ReviewAntibody therapeutics2020
Emerging antibody-based therapeutics against SARS-CoV-2 during the global pandemic.
Review in Antibody therapeutics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 45 citations in OpenAlex.
- Repurposing of lonafarnib as a treatment for SARS-CoV-2 infection.JCI insight · 2025Article
- Generation of recombinant viruses directly from clinical specimens of COVID-19 patients.Journal of clinical microbiology · 2024Article
- SARS-CoV-2 antibodies from children exhibit broad neutralization and belong to adult public clonotypes.Cell reports. Medicine · 2023Article
- The smallest functional antibody fragment: Ultralong CDR H3 antibody knob regions potently neutralize SARS-CoV-2.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- A scalable and high yielding SARS-CoV-2 spike protein receptor binding domain production process.Protein expression and purification · 2023Article
- Rapid, simple, and effective strategy to produce monoclonal antibodies targeting protein structures using hybridoma technology.Journal of biological engineering · 2023Article
- A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75.Cell reports · 2023Article
- Dendrimer-Peptide Conjugates for Effective Blockade of the Interactions between SARS-CoV-2 Spike Protein and Human ACE2 Receptor.Biomacromolecules · 2023Article
- A SARS-CoV-2 neutralizing antibody discovery by single cell sequencing and molecular modeling.Journal of biomedical research · 2022Article
- Manzamine-A Alters In Vitro Calvarial Osteoblast Function.Marine drugs · 2022Article
- Article
- Article
- Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Passive Immunotherapy Against SARS-CoV-2: From Plasma-Based Therapy to Single Potent Antibodies in the Race to Stay Ahead of the Variants.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2022Review
- Massively multiplexed affinity characterization of therapeutic antibodies against SARS-CoV-2 variants.Antibody therapeutics · 2022Article
- Article
- Clinical and experimental bacteriophage studies: Recommendations for possible approaches for standing against SARS-CoV-2.Microbial pathogenesis · 2022Review
- SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.Cell · 2022Article
- Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.bioRxiv : the preprint server for biology · 2021Article
- Polyclonal F(ab')iScience · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
SARS-CoV-2 antibody therapeutics are being evaluated in clinical and preclinical stages. As of 11 October 2020, 13 human monoclonal antibodies targeting the SARS-CoV-2 spike protein have entered clinical trials with three (REGN-COV2, LY3819253/LY-CoV555, and VIR-7831/VIR-7832) in phase 3. On 9 November 2020, the US Food and Drug Administration issued an emergency use authorization for bamlanivimab (LY3819253/LY-CoV555) for the treatment of mild-to-moderate COVID-19. This review outlines the development of neutralizing antibodies against SARS-CoV-2, with a focus on discussing various antibody discovery strategies (animal immunization, phage display and B cell cloning), describing binding epitopes and comparing neutralizing activities. Broad-neutralizing antibodies targeting the spike proteins of SARS-CoV-2 and SARS-CoV might be helpful for treating COVID-19 and future infections. VIR-7831/7832 based on S309 is the only antibody in late clinical development, which can neutralize both SARS-CoV-2 and SARS-CoV although it does not directly block virus receptor binding. Thus far, the only cross-neutralizing antibody that is also a receptor binding blocker is nanobody VHH-72. The feasibility of developing nanobodies as inhaled drugs for treating COVID-19 and other respiratory diseases is an attractive idea that is worth exploring and testing. A cocktail strategy such as REGN-COV2, or engineered multivalent and multispecific molecules, combining two or more antibodies might improve the efficacy and protect against resistance due to virus escape mutants. Besides the receptor-binding domain, other viral antigens such as the S2 subunit of the spike protein and the viral attachment sites such as heparan sulfate proteoglycans that are on the host cells are worth investigating.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.